On May 12, 2025, the White House announced an Executive Order aimed at lowering prescription drug costs for Americans. The order reintroduces the concept of “Most-Favored-Nation” (MFN) pricing, directing federal agencies to ensure Americans pay no more than other developed countries for certain prescription drugs.
Key directives in the order include:
- Communicating pricing targets directly to pharmaceutical manufacturers
- Allowing patients to purchase medications directly from manufacturers at MFN prices
- Expanding pricing alignment efforts to include both Medicare and Medicaid
- Requiring the Secretary of HHS to take action if manufacturers don’t comply voluntarily
While no official drug list has been published under this new order, the 2021 CMS list—created during a similar initiative—may offer early insight. That list included 50 high-expenditure Medicare Part B drugs, many of which are physician-administered and commonly appear in rebate-eligible claims.
Why This Matters
The Executive Order does not immediately change how rebates are calculated or paid, but it signals renewed federal focus on international pricing benchmarks and potential downstream effects on how drugs are reimbursed. If MFN pricing is implemented, it could impact rebate availability and structures, particularly for high-cost, physician-administered medications.
At VativoRx, we’re watching these developments closely. While it’s too early to assess the full impact, we’re proactively reviewing historical MFN drug codes and monitoring regulatory updates to stay ahead of any shifts that could affect rebate eligibility.
Policy may shift—but our commitment to compliance, transparency, and client support remains constant. If you’re looking for a rebate partner prepared to adapt with confidence, connect with us here.
